Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients and support obesity and weight-loss programs. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The Company’s applications of its technology include glucose monitoring, temperature monitoring, lactate monitoring, alcohol monitoring, and substance abuse monitoring. Its platform uses precision microsystems-based technology.
Follow-Up Questions
Nemaura Medical Inc 的 CEO 是誰？
Dr. Dewan Chowdhury 是 Nemaura Medical Inc 的 Chairman of the Board，自 2009 加入公司。
NMRD 股票的價格表現如何？
NMRD 的當前價格為 $0.0001，在上個交易日 decreased 了 0%。
Nemaura Medical Inc 的主要業務主題或行業是什麼？
Nemaura Medical Inc 屬於 Health Care 行業，該板塊是 Health Care
